<https://rdf.molmedb.upol.cz/reference/ref3233> <http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane46>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.7b00418"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM489897>;
	<http://purl.org/ontology/bibo/pmid> "28445037"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM489899>,
		<https://rdf.molmedb.upol.cz/interaction/method71>;
	<http://purl.org/dc/terms/bibliographicCitation> "Wang X, Kolesnikov A, Tay S, Chan G, Chao Q, Do S, Drummond J, Ebens AJ, Liu N, Ly J, Harstad E, Hu H, Moffat J, Munugalavadla V, Murray J, Slaga D, Tsui V, Volgraf M, Wallweber H, Chang JH.: Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability. J Med Chem, Volume 60 (10), 2017"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM489898>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource> .
<https://rdf.molmedb.upol.cz/interaction/int1009330> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3233> .
<https://rdf.molmedb.upol.cz/interaction/int1009329> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3233> .
<https://rdf.molmedb.upol.cz/interaction/int1009328> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3233> .